$VKTX

Eli Lilly dominates weight loss drugs with 60% U.S. market share and triple-digit growth, while Viking Therapeutics advances competitive VK2735. Lilly's 8% YTD decline and 28x forward earnings may offer value.

ACT Capital Management invests $7.25M in Viking Therapeutics, backing its obesity treatment candidate VK2735 showing 14.7% weight reduction in Phase 2 trials.

Eli Lilly strengthens obesity drug dominance as competitor's treatment fails trials and Lilly launches new monthly-dose Zepbound pen, commanding 60% market share.

Viking Therapeutics advances obesity drug VK2735 into Phase 3 trials after positive interim results, positioning itself in the competitive weight-loss pharmaceutical market.

Viking Therapeutics surged 10.91% after Novo Nordisk's obesity drug failed against Eli Lilly's competitor. Viking's dual injectable/oral candidate VK2735 offers differentiation entering Phase 3 trials.

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

Global health market reaches $6 trillion milestone by 2026, driven by consumer demand for wellness products. Companies expand through innovation in digital health, pharmaceuticals, and specialized care solutions.